AURE (AURE) Stock Price & Analysis
AURE (AURE) fell 3.01% to USD 2.42 as of June 10, 2026 at 12:17 UTC, according to Nexqual real-time market data.
AURE last closed at USD 2.49; the session ranged USD 2.33–2.43 on volume of 3,420 shares. Market capitalization is $88.87M, with a 52-week range of USD 1.5–14.6 (NCM). Source: Nexqual, June 10, 2026 at 12:17 UTC.
Key Statistics (as of June 10, 2026 at 12:17 UTC)
| Price | USD 2.42 |
|---|---|
| Change | ▼ 3.01% (down) |
| Previous Close | USD 2.49 |
| Open | USD 2.33 |
| Day Range | USD 2.33 – 2.43 |
| 52-Week Range | USD 1.5 – 14.6 |
| Volume | 3,420 shares |
| Market Cap | $88.87M |
| Exchange | NCM |
Technical Analysis (AURE)
Nexqual's technical model rates AURE "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 12:17 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 50.69 (neutral) |
| vs SMA50 | Above (USD 2.4) |
| MACD | 0.04 (positive) |
Analyst Ratings (AURE)
Wall Street analysts rate AURE "None", per Nexqual as of June 10, 2026 at 12:17 UTC.
| Consensus Rating | None |
|---|
Earnings (AURE)
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Financials & Fundamentals (AURE)
| Total Revenue | $1.79M |
|---|---|
| Gross Margin | -130.14% |
| Operating Margin | +505.91% |
| Profit Margin | -143.18% |
| ROE | -3.60% |
| Debt / Equity | 35.66 |
| Current Ratio | 59.94 |
| Total Cash | $2.07M |
| Total Debt | $41.20M |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Financial Health Score (AURE)
Nexqual rates AURE's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $2M cash vs $41M debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -4%, ROA 6.4% |
Ownership (AURE)
| Insider Ownership | +23.43% |
|---|---|
| Institutional Ownership | +12.91% |
| Shares Outstanding | 21.55M |
| Float | 7.97M |
| Short % of Float | +0.04% |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Leadership (AURE)
AURE is led by Bjorn Schmidtke (age 32), Chief Executive Officer, per Nexqual as of June 10, 2026 at 12:17 UTC.
| Chief Executive Officer | Bjorn Schmidtke (age 32) |
|---|
Major Backers & Investors (AURE)
Notable institutional backers of AURE include Yorkville Advisors Global, LP, according to Nexqual as of June 10, 2026 at 12:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yorkville Advisors Global, LP | 12.88% |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 2.18 | ▼ 1.14% |
| MGIH | Millennium Group International | USD 1.69 | ▲ 19.86% |
| VCIG | VCI Global Limited | USD 6.04 | ▼ 14.81% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.39 | ▼ 2.11% |
| GDC | GD Culture Group Limited | USD 0.1 | ▲ 2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:17 UTC. This page is informational and not investment advice.